Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$463.04 USD
-4.64 (-0.99%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $461.06 -1.98 (-0.43%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Thermo Fisher Scientific Inc. has a PEG ratio of 2.57 compared to the Medical - Instruments industry's PEG ratio of 2.25.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TMO 463.04 -4.64(-0.99%)
Will TMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMO
Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
TMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
Company News for Jul 24, 2025
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Other News for TMO
Putnam U.S. Large Cap Value Equity Concentrated SMA Q2 2025 Commentary
Decoding Thermo Fisher Scientific Inc (TMO): A Strategic SWOT Insight
Fortune Brands Innovations Inc: A Key Focus in First Pacific Advisors' Latest 13F Filing
Franklin U.S. Focused Growth SMA Q2 2025 Commentary
Franklin DynaTech SMA Q2 2025 Commentary